Assuntos
Buspirona/efeitos adversos , Transtorno Depressivo/tratamento farmacológico , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Sertralina/efeitos adversos , Síndrome de Abstinência a Substâncias/etiologia , Doença Aguda , Transtorno Depressivo/diagnóstico , Regulação para Baixo/efeitos dos fármacos , Feminino , Humanos , Pessoa de Meia-Idade , Receptores de Serotonina/efeitos dos fármacos , Receptores de Serotonina/metabolismo , Serotonina/metabolismo , Síndrome de Abstinência a Substâncias/metabolismo , SíndromeRESUMO
The lack of culturally appropriate psychometric instruments for the assessment of cognitive and emotional functioning in minority populations has been a concern often discussed in the assessment literature. With the increased focus on the measurement of outcome in mental health treatment, the lack of appropriate instruments for minorities has become readily apparent in this venue as well. We report on the Spanish translation of a brief and reliable measure of psychological health and well-being that has been shown to be sensitive to treatment outcomes. The original and Spanish translated versions of this measure are highly correlated, providing clinicians and organizations with a instrument that can be used for assessment of psychological well-being and treatment outcomes with Hispanic patients.
Assuntos
Hispânico ou Latino/psicologia , Transtornos Mentais/psicologia , Serviços de Saúde Mental , Avaliação de Resultados em Cuidados de Saúde , Escalas de Graduação Psiquiátrica , Aculturação , Adulto , Fatores Etários , Feminino , Humanos , Masculino , Transtornos Mentais/diagnóstico , Testes Psicológicos/estatística & dados numéricos , Psicometria , Valores de Referência , Sensibilidade e Especificidade , Fatores SexuaisRESUMO
The expected rise in prevalence rates of Alzheimer's disease over the next several decades has generated a great deal of attention at all levels of society, including governmental and scientific communities. These concerns have resulted in a vast number of research studies which have yielded medications focusing primarily on the symptomatic relief of the cognitive, neuropsychiatric and behavioral alterations felt to be pathognomic of the disease. Medical and pharmacological interventions which impact the onset or delay the progression of the illness are not yet readily available. We review and discuss the medications which are currently used for the symptomatic treatment and management of the disease, as well as discuss new pharmacological strategies which are under investigation and development.
